PGEN
NASDAQ · Biotechnology
Precigen Inc
$4.21
+0.06 (+1.45%)
Open$4.18
Previous Close$4.15
Day High$4.24
Day Low$4.11
52W High$5.47
52W Low$1.23
Volume—
Avg Volume2.84M
Market Cap1.47B
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,623.8% upside
Current
$4.21
$4.21
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.78M | 15.15M | 411.38M |
| Net Income | -279,386,775 | -353,455,295 | -34,816,902 |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% |
| EBITDA | -275,095,494 | -367,361,146 | -49,679,638 |
| Free Cash Flow | — | — | -21,385,787 |
| Rev Growth | -28.9% | -28.9% | +17.8% |
| Debt/Equity | 4.46 | 4.46 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |